Company Overview and News
Stepping aside for a minute from the "yields are soaring" mantra to look at few other-smaller, though very interesting, trends.
The September MLP Monthly Report can be found here offering insights on MLP industry news, the asset class’s performance, yields, valuations, and fundamental drivers.
KAAC APA SNSR AND LIT BFIT GXG SIL KRMA GXF CHII EV ACTX CHIE GOEX FINX CHIX SRET BOTZ CATH GURX GURI ALUM MILN CJHIQ URA BHI LNGR COPX QQQC GURU FANG
Marathon Oil has built an attractive oil and gas production portfolio in four major U.S. basins: Bakken, Eagle Ford, STACK/SCOOP, and Permian. It also has some overseas operations.
STT MQBKY BOE WPXP WLL SM CTLR MCQEF AXAS MPC WPX EV EOG OAS WTI MRO CLR MQG
Emerging markets have been one of the worst performing asset classes year-to-date, down nearly 12%, and over 20% since their January peak. The drivers of this poor performance include the strengthening U.S. dollar/weakening local currencies, growth concerns, and geopolitical risks. The recent turbulence in Turkey and Argentina has exacerbated the concerns in emerging markets, although both countries are relatively small components of the index.
WAEMX CICHY SCHE CICHF CCB EV CEO EEM 0939
LONDON, Oct 5 (Reuters) - World markets steadied ahead of U.S. jobs numbers on Friday, as a four-year high in oil prices and the biggest weekly jump in Treasury yields since February left investors wondering where to go next.
NEW YORK (Reuters) - The cost to insure debt holdings in electric carmaker Tesla Inc (TSLA.O) rose to its highest-ever level on Friday as the bond market reflected growing worries about a default, following the news that Chief Executive Elon Musk had been accused of fraud by federal regulators.
The coupons on high yield bonds are rising thanks to high interest rates and stable spreads.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to EV / Eaton Vance Corp. on message board site Silicon Investor.
as of ET